Induced pluripotent stem cell model recapitulates pathologic hallmarks of Gaucher disease

Proceedings of the National Academy of Sciences of the United States of America

Volumn 109, Issue 44, 2012, Pages 18054-18059

  Panicker, Leelamma M ^a   Miller, Diana ^a   Park, Tea Soon ^b,c   Patel, Brijesh ^a   Azevedo, Judi L ^a   Awad, Ola ^a   Masood, M Athar ^d   Veenstra, Timothy D ^d   Goldin, Ehud ^e   Stubblefield, Barbara K ^e   Tayebi, Nahid ^e   Polumuri, Swamy K ^a   Vogel, Stefanie N ^a   Sidransky, Ellen ^e   Zambidis, Elias T ^b,c   Feldman, Ricardo A ^a  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d SAIC FREDERICK INC   (United States)

^e NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

Author keywords

Erythrophagocytosis; Gaucher macrophages; Gaucher model; Glucosylsphingolipids; Lipid storage disease

Indexed keywords

GLUCOSYLCERAMIDASE; SPHINGOLIPID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL DIFFERENTIATION; CELL TYPE; CONTROLLED STUDY; DISEASE SEVERITY; GAUCHER DISEASE; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; KINETICS; MACROPHAGE; MACROPHAGE ACTIVATION; MOUSE; NONHUMAN; PHAGOCYTE; PHENOTYPE; PLURIPOTENT STEM CELL; PRIORITY JOURNAL; SKIN FIBROBLAST;

CELL DIFFERENTIATION; CELL LINEAGE; GAUCHER DISEASE; HUMANS; MACROPHAGE ACTIVATION; MODELS, BIOLOGICAL; PLURIPOTENT STEM CELLS;

EID: 84868089871     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1207889109     Document Type: Article

References (37)

1. Beutler E, Grabowski GA (2001) Gaucher Diseases. The Metabolic and Molecular Bases of Inherited Disease. III (McGraw-Hill, New York), pp 3635-3668.
2. Messner MC, Cabot MC (2010) Glucosylceramide in humans. Adv Exp Med Biol 688 (688):156-164.
3. Jmoudiak M, Futerman AH (2005) Gaucher disease: Pathological mechanisms and modern management. Br J Haematol 129(2):178-188.
4. Sidransky E (2004) Gaucher disease: Complexity in a "simple" disorder. Mol Genet Metab 83(1-2):6-15.
5. Goker-Alpan O, et al. (2005) Divergent phenotypes in Gaucher disease implicate the role of modifiers. J Med Genet 42(6):e37.
6. Takahashi K, Yamanaka S (2006) Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126(4):663-676.
7. Takahashi K, et al. (2007) Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131(5):861-872.
8. Park IH, et al. (2008) Disease-specific induced pluripotent stem cells. Cell 134(5):877-886.
9. Yu J, et al. (2007) Induced pluripotent stem cell lines derived from human somatic cells. Science 318(5858):1917-1920.
10. Dimos JT, et al. (2008) Induced pluripotent stem cells generated from patients with ALS can be differentiated into motor neurons. Science 321(5893):1218-1221.
11. Agarwal S, et al. (2010) Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature 464(7286):292-296.
12. Itzhaki I, et al. (2011) Modelling the long QT syndrome with induced pluripotent stem cells. Nature 471(7337):225-229.
13. Lahti AL, et al. (2012) Model for long QT syndrome type 2 using human iPS cells demonstrates arrhythmogenic characteristics in cell culture. Dis Model Mech 5(2):220-230.
14. Lee G, Studer L (2011) Modelling familial dysautonomia in human induced pluripotent stem cells. Philos Trans R Soc Lond B Biol Sci 366(1575):2286-2296.
15. Israel MA, et al. (2012) Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. Nature 482(7384):216-220.
16. Robinton DA, Daley GQ (2012) The promise of induced pluripotent stem cells in research and therapy. Nature 481(7381):295-305.
17. Bitton A, Etzell J, Grenert JP, Wang E (2004) Erythrophagocytosis in Gaucher cells. Arch Pathol Lab Med 128(10):1191-1192.
18. Machaczka M, Klimkowska M, Regenthal S, Hägglund H (2011) Gaucher disease with foamy transformed macrophages and erythrophagocytic activity. J Inherit Metab Dis 34(1):233-235.
19. Polumuri SK, Toshchakov VY, Vogel SN (2007) Role of phosphatidylinositol- 3 kinase in transcriptional regulation of TLR-induced IL-12 and IL-10 by Fc gamma receptor ligation in murine macrophages. J Immunol 179(1):236-246.
20. Naito M, Takahashi K, Hojo H (1988) An ultrastructural and experimental study on the development of tubular structures in the lysosomes of Gaucher cells. Lab Invest 58(5): 590-598.
21. Lee RE, Balcerzak SP, Westerman MP (1967) Gaucher's disease. A morphologic study and measurements of iron metabolism. Am J Med 42(6):891-898.
22. Hibbs RG, Ferrans VJ, Cipriano PR, Tardiff KJ (1970) A histochemical and electron microscopic study of Gaucher cells. Arch Pathol 89(2):137-153.
23. Kornhaber GJ, et al. (2008) Isofagomine induced stabilization of glucocerebrosidase. ChemBioChem 9(16):2643-2649.
24. Khanna R, et al. (2010) The pharmacological chaperone isofagomine increases the activity of the Gaucher disease L444P mutant form of beta-glucosidase. FEBS J 277(7):1618-1638.
25. Sun Y, et al. (2012) Ex vivo and in vivo effects of isofagomine on acid β-glucosidase variants and substrate levels in Gaucher disease. J Biol Chem 287(6):4275-4287.
26. Hruska KS, LaMarca ME, Scott CR, Sidransky E (2008) Gaucher disease: Mutation and polymorphism spectrum in the glucocerebrosidase gene (GBA). HumMutat 29(5):567-583.
27. Orvisky E, et al. (2002) Glucosylsphingosine accumulation in tissues from patients with Gaucher disease: Correlation with phenotype and genotype. Mol Genet Metab 76(4): 262-270.
28. Brady RO (2006) Enzyme replacement for lysosomal diseases. Annu Rev Med 57:283-296.
29. Goker-Alpan O (2011) Therapeutic approaches to bone pathology in Gaucher disease: Past, present and future. Mol Genet Metab 104(4):438-447.
30. Yu Z, Sawkar AR, Kelly JW (2007) Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS J 274(19):4944-4950.
31. Zheng W, et al. (2007) Three classes of glucocerebrosidase inhibitors identified by quantitative high-throughput screening are chaperone leads for Gaucher disease. Proc Natl Acad Sci USA 104(32):13192-13197.
32. Shen JS, Edwards NJ, HongYB,Murray GJ (2008) Isofagomine increases lysosomal delivery of exogenous glucocerebrosidase. Biochem Biophys Res Commun 369(4):1071-1075.
33. Steet RA, et al. (2006) The iminosugar isofagomine increases the activity of N370S mutant acid beta-glucosidase in Gaucher fibroblasts by several mechanisms. Proc Natl Acad Sci USA 103(37):13813-13818.
34. Settembre C, et al. (2008) A block of autophagy in lysosomal storage disorders. Hum Mol Genet 17(1):119-129.
35. Sun Y, Grabowski GA (2010) Impaired autophagosomes and lysosomes in neuronopathic Gaucher disease. Autophagy 6(5):648-649.
36. Goker-Alpan O, et al. (2008) The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 65(10):1353-1357.
37. Mazzulli JR, et al. (2011) Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 146(1):37-52.